Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Annals of Neurology|June 11, 2025
Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation Dynamics in Multiple SclerosisGiulio Disanto, Rosaria Sacco, Giulia Mallucci, et al.
Progress in Neurobiology|March 25, 2015
The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosisGiulia Mallucci, Luca Peruzzotti-Jametti, Joshua D Bernstock, et al.
Neuroscience|May 3, 2014
The role of the immune system in central nervous system plasticity after acute injuryLuca Peruzzotti-Jametti, Matteo Donegá, Elena Giusto, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 24, 2024
Impact of multiple sclerosis comorbidities on quality of life and job activityGiulia Mallucci, Maria Cristina Monti, Michela Ponzio, et al.
AJR. American Journal of Roentgenology|September 28, 2017
Do MRI Structured Reports for Multiple Sclerosis Contain Adequate Information for Clinical Decision Making?Francesco Alessandrino, Anna Pichiecchio, Giulia Mallucci, et al.
Pharmacological Research|April 12, 2017
What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under questionCristiana Pistono, Cecilia Osera, Chiara Boiocchi, et al.
Journal of Clinical Medicine|May 25, 2024
Tolerability and Acceptance of Switching from Brand to Generic Glatiramer Acetate in Multiple SclerosisIsabella Maraffi, Giulia Mallucci, Giulio Disanto, et al.
Environmental Science and Pollution Research International|September 7, 2020
PM<sub>2.5</sub> exposure as a risk factor for multiple sclerosis. An ecological study with a Bayesian mapping approachRoberto Bergamaschi, Maria Cristina Monti, Leonardo Trivelli, et al.
Multiple Sclerosis and Related Disorders|February 20, 2021
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patientsGiulia Mallucci, Antonio Zito, Fausto Baldanti, et al.
Multiple Sclerosis and Related Disorders|August 18, 2024
Persistent longitudinal T cell responses after SARS-CoV-2 mRNA vaccines in MS patients on different disease modifying treatmentsGiulio Disanto, Alice Galante, Rosaria Sacco, et al.
Pageof 5